Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases

BACKGROUND: Recent studies have suggested obesity could contribute to improved outcomes of immune checkpoint inhibitor (ICI)-based treatment. Non-alcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease, is also obesity-related, but its association with the efficacy of IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Juan, Zhou, Fei, Chu, Xiangling, Zhao, Jing, Wu, Yan, Zhao, Wencheng, Xu, Chuan, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225134/
https://www.ncbi.nlm.nih.gov/pubmed/32420071
http://dx.doi.org/10.21037/tlcr.2020.04.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225134/
https://www.ncbi.nlm.nih.gov/pubmed/32420071
http://dx.doi.org/10.21037/tlcr.2020.04.15

Ejemplares similares